138 related articles for article (PubMed ID: 12392705)
1. pH Dependence of inhibitors targeting the occluding loop of cathepsin B.
Cathers BE; Barrett C; Palmer JT; Rydzewski RM
Bioorg Chem; 2002 Aug; 30(4):264-75. PubMed ID: 12392705
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex.
Yamamoto A; Tomoo K; Matsugi K; Hara T; In Y; Murata M; Kitamura K; Ishida T
Biochim Biophys Acta; 2002 Jun; 1597(2):244-51. PubMed ID: 12044902
[TBL] [Abstract][Full Text] [Related]
3. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction.
Sumiya S; Yoneda T; Kitamura K; Murata M; Yokoo C; Tamai M; Yamamoto A; Inoue M; Ishida T
Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):299-303. PubMed ID: 1606628
[TBL] [Abstract][Full Text] [Related]
4. Epoxysuccinyl dipeptides as selective inhibitors of cathepsin B.
Gour-Salin BJ; Lachance P; Plouffe C; Storer AC; Ménard R
J Med Chem; 1993 Mar; 36(6):720-5. PubMed ID: 8459399
[TBL] [Abstract][Full Text] [Related]
5. The binding mode of an E-64 analog to the active site of cathepsin B.
Feng MH; Chan SL; Xiang Y; Huber CP; Lim C
Protein Eng; 1996 Nov; 9(11):977-86. PubMed ID: 8961350
[TBL] [Abstract][Full Text] [Related]
6. The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide.
Quraishi O; Nägler DK; Fox T; Sivaraman J; Cygler M; Mort JS; Storer AC
Biochemistry; 1999 Apr; 38(16):5017-23. PubMed ID: 10213604
[TBL] [Abstract][Full Text] [Related]
7. Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration By release of loop anchoring through mutation of his110.
Pavlova A; Krupa JC; Mort JS; Abrahamson M; Björk I
FEBS Lett; 2000 Dec; 487(2):156-60. PubMed ID: 11150500
[TBL] [Abstract][Full Text] [Related]
8. Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B.
Yoon MC; Christy MP; Phan VV; Gerwick WH; Hook G; O'Donoghue AJ; Hook V
Biochemistry; 2022 Feb; 61(4):228-238. PubMed ID: 35119840
[TBL] [Abstract][Full Text] [Related]
9. Cathepsins X and B display distinct activity profiles that can be exploited for inhibitor design.
Ménard R; Therrien C; Lachance P; Sulea T; Qo H; Alvarez-Hernandez AD; Roush WR
Biol Chem; 2001 May; 382(5):839-45. PubMed ID: 11517939
[TBL] [Abstract][Full Text] [Related]
10. Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases.
Martichonok V; Plouffe C; Storer AC; Ménard R; Jones JB
J Med Chem; 1995 Aug; 38(16):3078-85. PubMed ID: 7636871
[TBL] [Abstract][Full Text] [Related]
11. E-64 analogues as inhibitors of cathepsin B. On the role of the absolute configuration of the epoxysuccinyl group.
Schaschke N; Assfalg-Machleidt I; Machleidt W; Turk D; Moroder L
Bioorg Med Chem; 1997 Sep; 5(9):1789-97. PubMed ID: 9354234
[TBL] [Abstract][Full Text] [Related]
12. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity.
Musil D; Zucic D; Turk D; Engh RA; Mayr I; Huber R; Popovic T; Turk V; Towatari T; Katunuma N
EMBO J; 1991 Sep; 10(9):2321-30. PubMed ID: 1868826
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Structure-Activity Relationship Study of Epoxysuccinyl-Peptide Derivatives as Cathepsin B Inhibitors.
Zhang X; Yang X; Wang H; Li S; Guo K; Jiang D; Xiao J; Liang D
Biol Pharm Bull; 2017 Aug; 40(8):1240-1246. PubMed ID: 28502922
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin B inhibitors do not prevent the intracellular trypsinogen activation by secretagogue hyperstimulation.
Otani T; Matsukura A
Pancreas; 1999 Aug; 19(2):210-1. PubMed ID: 10438171
[No Abstract] [Full Text] [Related]
15. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs.
Bogyo M; Verhelst S; Bellingard-Dubouchaud V; Toba S; Greenbaum D
Chem Biol; 2000 Jan; 7(1):27-38. PubMed ID: 10662686
[TBL] [Abstract][Full Text] [Related]
16. Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex.
Yamamoto A; Tomoo K; Hara T; Murata M; Kitamura K; Ishida T
J Biochem; 2000 Apr; 127(4):635-43. PubMed ID: 10739956
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
18. Two-step mechanism of inhibition of cathepsin B by cystatin C due to displacement of the proteinase occluding loop.
Nycander M; Estrada S; Mort JS; Abrahamson M; Björk I
FEBS Lett; 1998 Jan; 422(1):61-4. PubMed ID: 9475170
[TBL] [Abstract][Full Text] [Related]
19. X-ray crystal structure of papain complexed with cathepsin B-specific covalent-type inhibitor: substrate specificity and inhibitory activity.
Matsumoto K; Murata M; Sumiya S; Mizoue K; Kitamura K; Ishida T
Biochim Biophys Acta; 1998 Mar; 1383(1):93-100. PubMed ID: 9546050
[TBL] [Abstract][Full Text] [Related]
20. Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor.
Tomoo K
Curr Top Med Chem; 2010; 10(7):696-707. PubMed ID: 20337581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
